R

Relmada Therapeutics
D

RLMD

3.42000
USD
0.08
(2.40%)
Market Closed
Volume
1,626
EPS
0
Div Yield
0
P/E
-1
Market Cap
103,195,771
OverviewSignalsIdeasNews
Related Instruments
    A
    ALT
    -0.27000
    (-4.24%)
    6.10000 USD
    B
    BCRX
    -0.19000
    (-2.61%)
    7.10000 USD
    I
    INO
    -0.670
    (-6.28%)
    10.000 USD
    MRNA
    -25.020
    (-20.99%)
    94.160 USD
    N
    NVAX
    -0.250
    (-1.95%)
    12.560 USD
    T
    TNXP
    0.00960
    (1.92%)
    0.51050 USD
    V
    VXRT
    -0.01170
    (-1.74%)
    0.65890 USD
News

Title: Relmada Therapeutics

Sector: Healthcare
Industry: Biotechnology
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment ofdepression and other potential indications.